-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Misses Q3 EPS by 19c
-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Actio
-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
461,078 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

